Oncolytics Stock Based Compensation vs Begin Period Cash Flow Analysis

ONC Stock

CAD 0.77 0.01 1.28%

Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Stock Based Compensation and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Stock Based Compensation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Oncolytics Biotech's Stock Based Compensation and Begin Period Cash Flow is 0.46. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Stock Based Compensation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Oncolytics Biotech are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Oncolytics Biotech's Stock Based Compensation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.46

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is very stable compared to the past year. As of the 20th of April 2025, Enterprise Value is likely to grow to about 116.7 M, while Tax Provision is likely to drop about 85 K.

	2022	2023	2024	2025 (projected)
Net Interest Income	528K	1.3M	1.2M	1.3M
Interest Income	528K	1.3M	1.2M	1.8M

Net Interest Income Interest Income

Oncolytics Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Non Currrent Assets Other	Short Term Investments	Short Term Debt	Other Assets	Other Current Liab	Common Stock
Total Assets		0.29	-0.01	0.83	0.45	-0.78	-0.51	-0.09	0.85	-0.1	0.85	-0.13	0.53	0.39	0.57	0.48	0.28	0.36	1.0	-0.46	0.46	-0.04	-0.47	-0.09	0.04	0.47
Short Long Term Debt Total	0.29		0.37	0.31	0.39	-0.37	-0.27	0.4	0.45	-0.78	0.33	0.22	-0.11	-0.02	-0.09	0.23	0.14	-0.03	0.34	-0.73	0.23	-0.49	-0.67	-0.64	-0.15	0.2
Total Current Liabilities	-0.01	0.37		-0.3	0.32	-0.03	-0.21	0.49	-0.02	-0.33	0.05	0.31	-0.01	0.13	0.05	0.28	0.66	0.17	0.01	-0.43	0.2	-0.17	-0.42	-0.21	0.59	0.1
Total Stockholder Equity	0.83	0.31	-0.3		0.12	-0.6	-0.09	0.05	0.79	-0.2	0.68	-0.24	0.11	-0.06	0.14	0.05	-0.26	-0.09	0.84	-0.23	0.29	-0.05	-0.17	-0.26	-0.2	0.16
Property Plant And Equipment Net	0.45	0.39	0.32	0.12		-0.61	-0.8	-0.29	0.37	0.03	0.74	-0.08	0.75	0.65	0.75	0.83	0.66	0.78	0.45	-0.5	0.38	-0.16	-0.54	0.17	0.08	0.84
Net Debt	-0.78	-0.37	-0.03	-0.6	-0.61		0.49	0.12	-0.91	0.18	-0.87	0.27	-0.55	-0.34	-0.56	-0.49	-0.28	-0.59	-0.78	0.44	-0.04	0.31	0.43	-0.16	0.0	-0.47
Retained Earnings	-0.51	-0.27	-0.21	-0.09	-0.8	0.49		0.39	-0.3	0.06	-0.6	-0.05	-0.87	-0.83	-0.87	-0.98	-0.75	-0.79	-0.5	0.67	-0.33	0.02	0.76	-0.16	0.05	-0.91
Accounts Payable	-0.09	0.4	0.49	0.05	-0.29	0.12	0.39		-0.01	-0.56	-0.11	0.06	-0.57	-0.64	-0.57	-0.31	-0.2	-0.39	-0.05	-0.31	-0.19	-0.46	-0.17	-0.52	-0.06	-0.54
Cash	0.85	0.45	-0.02	0.79	0.37	-0.91	-0.3	-0.01		-0.34	0.76	-0.21	0.29	0.18	0.32	0.26	0.11	0.25	0.86	-0.41	0.13	-0.22	-0.38	-0.1	0.03	0.28
Non Current Assets Total	-0.1	-0.78	-0.33	-0.2	0.03	0.18	0.06	-0.56	-0.34		-0.05	-0.21	0.36	0.24	0.35	-0.02	0.04	0.27	-0.16	0.7	0.23	0.33	0.63	0.67	0.19	0.08
Cash And Short Term Investments	0.85	0.33	0.05	0.68	0.74	-0.87	-0.6	-0.11	0.76	-0.05		-0.31	0.66	0.4	0.67	0.64	0.32	0.59	0.84	-0.48	0.28	-0.18	-0.47	0.1	-0.06	0.65
Net Receivables	-0.13	0.22	0.31	-0.24	-0.08	0.27	-0.05	0.06	-0.21	-0.21	-0.31		-0.15	0.19	-0.04	-0.02	0.29	-0.18	-0.12	-0.12	0.19	0.1	-0.26	-0.27	0.14	0.0
Common Stock Shares Outstanding	0.53	-0.11	-0.01	0.11	0.75	-0.55	-0.87	-0.57	0.29	0.36	0.66	-0.15		0.82	0.98	0.89	0.65	0.9	0.49	-0.3	0.29	0.03	-0.4	0.54	0.01	0.86
Non Current Liabilities Total	0.39	-0.02	0.13	-0.06	0.65	-0.34	-0.83	-0.64	0.18	0.24	0.4	0.19	0.82		0.87	0.77	0.82	0.67	0.37	-0.28	0.44	0.33	-0.46	0.3	0.23	0.82
Other Current Assets	0.57	-0.09	0.05	0.14	0.75	-0.56	-0.87	-0.57	0.32	0.35	0.67	-0.04	0.98	0.87		0.87	0.71	0.87	0.54	-0.31	0.34	0.12	-0.43	0.48	0.1	0.86
Other Stockholder Equity	0.48	0.23	0.28	0.05	0.83	-0.49	-0.98	-0.31	0.26	-0.02	0.64	-0.02	0.89	0.77	0.87		0.75	0.85	0.47	-0.65	0.28	-0.11	-0.73	0.24	-0.03	0.9
Total Liab	0.28	0.14	0.66	-0.26	0.66	-0.28	-0.75	-0.2	0.11	0.04	0.32	0.29	0.65	0.82	0.71	0.75		0.65	0.27	-0.45	0.4	0.11	-0.58	0.15	0.5	0.63
Property Plant And Equipment Gross	0.36	-0.03	0.17	-0.09	0.78	-0.59	-0.79	-0.39	0.25	0.27	0.59	-0.18	0.9	0.67	0.87	0.85	0.65		0.33	-0.34	0.05	-0.25	-0.4	0.6	0.04	0.71
Total Current Assets	1.0	0.34	0.01	0.84	0.45	-0.78	-0.5	-0.05	0.86	-0.16	0.84	-0.12	0.49	0.37	0.54	0.47	0.27	0.33		-0.5	0.44	-0.05	-0.5	-0.14	0.02	0.46
Intangible Assets	-0.46	-0.73	-0.43	-0.23	-0.5	0.44	0.67	-0.31	-0.41	0.7	-0.48	-0.12	-0.3	-0.28	-0.31	-0.65	-0.45	-0.34	-0.5		-0.12	0.32	0.97	0.46	0.18	-0.44
Non Currrent Assets Other	0.46	0.23	0.2	0.29	0.38	-0.04	-0.33	-0.19	0.13	0.23	0.28	0.19	0.29	0.44	0.34	0.28	0.4	0.05	0.44	-0.12		0.21	-0.18	-0.27	0.34	0.39
Short Term Investments	-0.04	-0.49	-0.17	-0.05	-0.16	0.31	0.02	-0.46	-0.22	0.33	-0.18	0.1	0.03	0.33	0.12	-0.11	0.11	-0.25	-0.05	0.32	0.21		0.21	-0.05	0.25	0.1
Short Term Debt	-0.47	-0.67	-0.42	-0.17	-0.54	0.43	0.76	-0.17	-0.38	0.63	-0.47	-0.26	-0.4	-0.46	-0.43	-0.73	-0.58	-0.4	-0.5	0.97	-0.18	0.21		0.39	0.15	-0.55
Other Assets	-0.09	-0.64	-0.21	-0.26	0.17	-0.16	-0.16	-0.52	-0.1	0.67	0.1	-0.27	0.54	0.3	0.48	0.24	0.15	0.6	-0.14	0.46	-0.27	-0.05	0.39		0.11	0.26
Other Current Liab	0.04	-0.15	0.59	-0.2	0.08	0.0	0.05	-0.06	0.03	0.19	-0.06	0.14	0.01	0.23	0.1	-0.03	0.5	0.04	0.02	0.18	0.34	0.25	0.15	0.11		-0.02
Common Stock	0.47	0.2	0.1	0.16	0.84	-0.47	-0.91	-0.54	0.28	0.08	0.65	0.0	0.86	0.82	0.86	0.9	0.63	0.71	0.46	-0.44	0.39	0.1	-0.55	0.26	-0.02

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	34.3M	45.9M	37.3M	38.8M	20.2M	30.1M
Short Long Term Debt Total	402.1K	654.8K	373K	423K	486.5K	301.2K
Total Current Liabilities	2.7M	2.7M	3.9M	4.2M	6.7M	4.1M
Total Stockholder Equity	24.8M	36.1M	26.5M	27.6M	6.0M	5.7M
Property Plant And Equipment Net	609.1K	976.3K	652K	647K	1.3M	664.5K
Net Debt	(30.8M)	(40.6M)	(11.3M)	(34.5M)	(31.0M)	(29.5M)
Retained Earnings	(367.1M)	(393.4M)	(418.3M)	(446.0M)	(477.7M)	(453.8M)
Accounts Payable	1.8K	594K	2.3M	1.1M	1.1M	1.0M
Cash	31.2M	41.3M	11.7M	34.9M	15.9M	19.3M
Non Current Assets Total	609.1K	976.3K	1.7M	647K	1.3M	1.8M
Cash And Short Term Investments	31.2M	41.3M	32.1M	34.9M	40.1M	26.6M
Net Receivables	89.7K	866.1K	521K	15K	17.3K	16.4K
Common Stock Shares Outstanding	40.3M	53.5M	58.0M	67.6M	77.1M	80.9M
Liabilities And Stockholders Equity	34.3M	45.9M	37.3M	38.8M	44.6M	30.5M
Non Current Liabilities Total	6.9M	7.1M	6.9M	7.0M	7.5M	7.9M
Other Current Assets	2.4M	2.8M	3.0M	3.2M	3.7M	3.9M
Other Stockholder Equity	31.0M	34.2M	40.1M	42.1M	48.4M	42.9M
Total Liab	9.6M	9.8M	10.8M	11.3M	14.2M	14.9M
Property Plant And Equipment Gross	609.1K	976.3K	652K	1.3M	1.9M	2.0M
Total Current Assets	33.7M	44.9M	35.7M	38.2M	18.9M	27.7M
Accumulated Other Comprehensive Income	400.2K	387.7K	662K	544K	489.6K	465.1K
Short Term Investments	30.4M	1.4M	20.5M	3.4M	3.0M	2.9M
Short Term Debt	248.9K	294K	216K	133K	119.7K	113.7K
Other Current Liab	2.5M	1.8M	1.5M	3.0M	1.6M	2.3M
Common Stock	356.8M	391.3M	404.0M	430.9M	495.5M	310.7M
Net Tangible Assets	(107.9K)	24.8M	36.1M	26.5M	30.5M	19.0M
Property Plant Equipment	727.5K	609.1K	976.3K	652K	749.8K	610.4K
Capital Surpluse	33.0M	34.6M	37.8M	40.1M	46.1M	35.9M
Long Term Debt Total	166.4K	153.2K	361.1K	157K	180.6K	131.6K
Cash And Equivalents	1.1M	858.0K	1.4M	11.7M	13.4M	14.1M
Current Deferred Revenue	(3.2K)	(1.8K)	(594K)	(1.1M)	(973.8K)	(925.1K)
Net Invested Capital	24.8M	36.1M	26.5M	27.6M	6.0M	5.7M
Net Working Capital	31.0M	42.2M	31.7M	33.9M	12.2M	11.6M
Capital Stock	356.8M	391.3M	404.0M	430.9M	438.2M	411.3M
Capital Lease Obligations	402.1K	654.8K	373K	423K	1.1M	627.6K

Pair Trading with Oncolytics Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Oncolytics Stock

0.62	NG	NovaGold Resources	Pair Corr
0.82	HPQ	HPQ Silicon Resources	Pair Corr
0.85	GS	GOLDMAN SACHS CDR	Pair Corr

Moving against Oncolytics Stock

0.39

DFR

Diamond Fields Resources

Pair Corr

The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.

The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:

How To Invest In Oncolytics

Details

Is Oncolytics Stock a good investment?

Details

What is Oncolytics Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Stock Based Compensation vs Begin Period Cash Flow Analysis

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Begin Period Cash Flow

Oncolytics Biotech fundamental ratios Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech fundamental ratios Accounts

Pair Trading with Oncolytics Biotech

Moving together with Oncolytics Stock

Moving against Oncolytics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Other Current Assets	+ 0.98	Common Stock Shares Outstanding
Short Term Debt	+ 0.97	Intangible Assets
Property Plant And Equipment Gross	+ 0.9	Common Stock Shares Outstanding
Common Stock	+ 0.9	Other Stockholder Equity
Other Stockholder Equity	+ 0.89	Common Stock Shares Outstanding

Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock	- 0.91	Retained Earnings
Cash	- 0.91	Net Debt
Other Current Assets	- 0.87	Retained Earnings
Common Stock Shares Outstanding	- 0.87	Retained Earnings
Cash And Short Term Investments	- 0.87	Net Debt